Novanta Announces Financial Results for the Second Quarter 2022

09 Aug 2022
www.biospace.com
Financial StatementAcquisition
Aug. 9, 2022 10:59 UTC Second Quarter 2022 GAAP Revenue increased 29% to $215 million Second Quarter 2022 GAAP Consolidated Net Income of $17.5 million Second Quarter 2022 GAAP Diluted Earnings Per Share increased 48% to $0.49 Second Quarter 2022 Adjusted Earnings Per Share increased 26% to $0.78 Second Quarter 2022 Adjusted EBITDA of $45.0 million Raises Full Year Guidance BEDFORD, Mass.--(BUSINESS WIRE)-- Novanta Inc. (Formerly Known As GSI Group) (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the second quarter 2022. Financial Highlights Three Months Ended (In millions, except per share amounts) July 1, July 2, 2022 2021 GAAP Revenue $ 215.4 $ 167.5 Operating Income $ 23.3 $ 16.0 Consolidated Net Income $ 17.5 $ 11.7 Diluted EPS $ 0.49 $ 0.33 Non-GAAP* Adjusted Operating Income $ 36.7 $ 28.7 Adjusted Diluted EPS $ 0.78 $ 0.62 Adjusted EBITDA $ 45.0 $ 37.0 *Reconciliations of GAAP to non-GAAP financial measures, as well as definitions for the non-GAAP financial measures included in this press release and the reasons for their use, are presented below. “Novanta achieved exceptionally strong financial results in the second quarter, with double-digit growth for sales, Adjusted EBITDA, and EPS,” said Matthijs Glastra, Chair and Chief Executive Officer of Novanta. “Customer demand continues to be healthy across our medical and advanced industrial application areas, with bookings up 25% year over year, giving us a new record level of backlog at $653 million. The diversification of our portfolio is helping us to navigate through the ongoing macroeconomic environment difficulties, and we continue to expand in attractive application areas with outstanding progress in our design wins.” Second Quarter During the second quarter of 2022, Novanta generated GAAP revenue of $215.4 million, an increase of $47.8 million, or 28.6%, versus the second quarter of 2021. The Company’s acquisition activities resulted in an increase in revenue of $34.9 million, or 20.9%, compared to the second quarter of 2021. Changes in foreign currency exchange rates year over year adversely impacted our revenue by $8.6 million, or 5.2%, during the second quarter of 2022. Our year-over-year Organic Revenue Growth, which excludes the net impact of acquisitions and changes in foreign currency exchange rates, was an increase of 12.9% for the second quarter of 2022 (see “Organic Revenue Growth” in the non-GAAP reconciliations below). In the second quarter of 2022, GAAP operating income was $23.3 million, compared to $16.0 million in the second quarter of 2021. GAAP consolidated net income was $17.5 million in the second quarter of 2022, compared to $11.7 million in the second quarter of 2021. GAAP diluted earnings per share (“EPS”) was $0.49 in the second quarter of 2022, compared to $0.33 in the second quarter of 2021. Adjusted Diluted EPS was $0.78 in the second quarter of 2022, compared to $0.62 in the second quarter of 2021. The Company ended the second quarter of 2022 with 35.9 million diluted weighted average shares outstanding. Adjusted EBITDA was $45.0 million in the second quarter of 2022, compared to $37.0 million in the second quarter of 2021. Operating cash flow for the second quarter of 2022 was $24.1 million. The Company completed the second quarter of 2022 with approximately $407.4 million of total debt and $100.5 million of total cash. Net Debt, as defined in the non-GAAP reconciliation below, was $312.3 million. Financial Guidance “Our strong first half performance gives us confidence to raise our outlook for the full year. For the third quarter, we expect to maintain momentum with strong double-digit revenue growth due to our consistently strong customer demand and record levels of backlog.” said Matthijs Glastra. “Our teams are working diligently to counteract the continued supply chain constraints, inflationary pressures, and foreign exchange challenges, yet we continue to see a strong full year, despite the macroeconomic environment.” For the third quarter of 2022, the Company expects GAAP revenue of approximately $214 million to $216 million, demonstrating reported growth of 20% to 22%. The Company expects Adjusted Gross Profit Margin to be approximately 46.0%. The Company expects Adjusted EBITDA to be in the range of $43.5 million to $45.5 million and Adjusted Diluted EPS to be in the range of $0.71 to $0.76. The Company’s guidance assumes no significant changes in foreign exchange rates. For the full year 2022, the Company expects GAAP revenue of approximately $848 million to $852 million, demonstrating reported growth of 20% to 21%. The Company expects Adjusted Gross Profit Margin to be approximately 46.0%. The Company expects Adjusted EBITDA to be in the range of $177 million to $180 million and Adjusted Diluted EPS to be in the range of $2.96 to $3.02. The Company’s guidance assumes no significant changes in foreign exchange rates. Novanta provides earnings guidance on a non-GAAP basis and does not provide earnings guidance on a GAAP basis, with the exception of GAAP revenue guidance. A reconciliation of the Company’s forward-looking Adjusted Gross Profit Margin, Adjusted EBITDA and Adjusted Diluted EPS guidance to the most directly comparable GAAP financial measures is not provided because of the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliations, including future changes in the fair value of contingent considerations; significant discrete income tax expenses (benefits); divestitures and related expenses; acquisitions and related expenses; impact of purchase price allocations for recently completed acquisitions; gains and losses from sale of real estate assets; costs related to product line closures; intangible asset impairment charges and related asset write-offs; future restructuring expenses; foreign exchange gains/(losses); benefits or expenses associated with the completion of tax audits; and other charges reflected in the Company’s reconciliation of historical non-GAAP financial measures, the amounts of which, based on past experience, could be material. For additional information regarding Novanta’s non-GAAP financial measures, see “Use of Non-GAAP Financial Measures” below. Conference Call Information The Company will host a conference call on Tuesday, August 9, 2022 at 10:00 a.m. ET to discuss these results and to provide a business update. To access the call, please dial (888) 346-3959 prior to the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company’s website at . A replay of the audio webcast will be available approximately three hours after the conclusion of the call in the Investor Relations section of the Company’s website at . The replay will remain available until Monday, October 3, 2022. Use of Non-GAAP Financial Measures The non-GAAP financial measures used in this press release are Organic Revenue Growth, Adjusted Gross Profit, Adjusted Gross Profit Margin, Adjusted Operating Income and Operating Margin, Adjusted Income before Income Taxes, Adjusted Income Tax Provision/(Benefit) and Effective Tax Rate, Adjusted Consolidated Net Income, Adjusted Diluted EPS, Adjusted EBITDA, Adjusted EBITDA Margin, Free Cash Flow, Free Cash Flow as a Percentage of Consolidated Net Income, and Net Debt. The Company believes that these non-GAAP financial measures provide useful and supplementary information to investors regarding the operating performance of the Company. It is management’s belief that these non-GAAP financial measures would be particularly useful to investors because of the significant changes that have occurred outside of the Company’s day-to-day business in accordance with the execution of the Company’s strategy. This strategy includes streamlining the Company’s existing operations through site and functional consolidations, strategic divestitures and product line closures, expanding the Company’s business through significant internal investments, and broadening the Company’s product and service offerings through acquisition of innovative and complementary technologies and solutions. The financial impact of certain elements of these activities, particularly acquisitions, divestitures, and site and functional restructurings, is often large relative to the Company’s overall financial performance and can adversely affect the comparability of its operating results and investors’ ability to analyze the business from period to period. The Company’s Adjusted EBITDA, Organic Revenue Growth and Adjusted Gross Margin are used by management to evaluate operating performance, communicate financial results to the Board of Directors, benchmark results against historical performance and the performance of peers, and evaluate investment opportunities, including acquisitions and divestitures. In addition, Adjusted EBITDA, Organic Revenue Growth and Adjusted Gross Margins are used to determine bonus payments for senior management and employees. The Company also uses Adjusted Diluted EPS as a measurement for performance-based restricted stock units issued to certain executives. Accordingly, the Company believes that these non-GAAP financial measures provide greater transparency and insight into management’s method of analysis. Non-GAAP financial measures should not be considered as substitutes for, or superior to, measures of financial performance prepared in accordance with GAAP. They are limited in value because they exclude charges that have a material effect on the Company’s reported results and, therefore, should not be relied upon as the sole financial measures to evaluate the Company’s financial results. The non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with, GAAP financial measures. Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures as provided in the tables accompanying this press release. Safe Harbor and Forward-Looking Information Certain statements in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and are based on current expectations and assumptions that are subject to risks and uncertainties. All statements contained in this news release that do not relate to matters of historical fact should be considered forward-looking statements, and are generally identified by words such as “expect,” “intend,” “anticipate,” “estimate,” “believe,” “future,” “could,” “should,” “plan,” “aim,” and other similar expressions. These forward-looking statements include, but are not limited to, statements regarding anticipated financial performance and financial position, including our financial outlook for the third quarter and full year; statements regarding the COVID-19 pandemic; expectations for our end markets and market position; expectations regarding our ability to mitigate supply chain disruptions; inflationary pressures; expectations regarding the benefits of recent acquisitions; expectations regarding our design win and customer order activities and long-term prospects in our medical and advanced industrial end-markets; and other statements that are not historical facts. These forward-looking statements are neither promises nor guarantees, but involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, but not limited to, the following: economic and political conditions and the effects of these conditions on our customers’ businesses, capital expenditures and level of business activities; risks associated with the COVID-19 pandemic and other events outside our control; our dependence upon our ability to respond to fluctuations in product demand; our ability to continually innovate, introduce new products timely, and successfully commercialize our innovations; failure to introduce new products in a timely manner; customer order timing and other similar factors beyond our control; disruptions or breaches in security of our and our third-party providers’ information technology systems; our failure to comply with data privacy regulations; changes in interest rates, credit ratings or foreign currency exchange rates; risks associated with our operations in foreign countries; our increased use of outsourcing in foreign countries; risks associated with increased outsourcing of components manufacturing; our exposure to increased tariffs, trade restrictions or taxes on our products; negative effects on global economic conditions, financial markets and our business as a result of the United Kingdom’s withdrawal from the European Union; violations of our intellectual property rights and our ability to protect our intellectual property against infringement by third parties; risk of losing our competitive advantage; our failure to successfully integrate recent and future acquisitions into our business; our ability to attract and retain key personnel; our restructuring and realignment activities and disruptions to our operations as a result of consolidation of our operations; product defects or problems integrating our products with other vendors’ products; disruptions in the supply of certain key components or other goods from our suppliers; our failure to accurately forecast component and raw material requirements leading to excess inventories or delays in the delivery of our products; production difficulties and product delivery delays or disruptions; our exposure to medical device regulations, which may impede or hinder the approval or sale of our products and, in some cases, may ultimately result in an inability to obtain approval of certain products or may result in the recall or seizure of previously approved products; potential penalties for violating foreign, U.S. federal, and state healthcare laws and regulations; impact of healthcare industry cost containment and healthcare reform measures; changes in governmental regulations affecting our business or products; our failure to implement new information technology systems and software successfully; our failure to realize the full value of our intangible assets; increasing scrutiny and changing expectations from investors, customers, and governments with respect to Environmental, Social and Governance policies and practices; our exposure to the credit risk of some of our customers and in weakened markets; our reliance on third party distribution channels; our reliance on original equipment manufacturer customers; being subject to U.S. federal income taxation even though we are a non-U.S. corporation; changes in tax laws, and fluctuations in our effective tax rates; any need for additional capital to adequately respond to business challenges or opportunities and repay or refinance our existing indebtedness, which may not be available on acceptable terms or at all; our existing indebtedness limiting our ability to engage in certain activities; volatility in the market price for our common shares; and our failure to maintain appropriate internal controls in the future. Other important risk factors that could affect the outcome of the events set forth in these statements and that could affect the Company’s operating results and financial condition are discussed in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, as updated by our future filings with the Securities and Exchange Commission. Such statements are based on the Company’s beliefs and assumptions and on information currently available to the Company. The Company disclaims any obligation to publicly update or revise any such forward-looking statements as a result of developments occurring after the date of this document except as required by law. About Novanta Novanta is a leading global supplier of core technology solutions that give medical and advanced industrial original equipment manufacturers a competitive advantage. We combine deep proprietary technology expertise and competencies in photonics, vision, and precision motion with a proven ability to solve complex technical challenges. This enables Novanta to engineer core components and sub-systems that deliver extreme precision and performance, tailored to our customers' demanding applications. The driving force behind our growth is the team of innovative professionals who share a commitment to innovation and customer success. Novanta’s common shares are quoted on Nasdaq under the ticker symbol “NOVT.” More information about Novanta is available on the Company’s website at . For additional information, please contact Novanta Investor Relations at (781) 266-5137 or InvestorRelations@novanta.com. NOVANTA INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands of U.S. dollars or shares, except per share amounts) (Unaudited) Three Months Ended July 1, July 2, 2022 2021 Revenue $ 215,356 $ 167,523 Cost of revenue 120,111 95,117 Gross profit 95,245 72,406 Operating expenses: Research and development and engineering 21,588 16,954 Selling, general and administrative 40,538 31,240 Amortization of purchased intangible assets 7,173 3,586 Restructuring, acquisition, and related costs 2,655 4,634 Total operating expenses 71,954 56,414 Operating income 23,291 15,992 Interest income (expense), net (2,757 ) (1,378 ) Foreign exchange transaction gains (losses), net 152 (76 ) Other income (expense), net 68 (97 ) Income before income taxes 20,754 14,441 Income tax provision (benefit) 3,275 2,777 Consolidated net income $ 17,479 $ 11,664 Earnings per common share: Basic $ 0.49 $ 0.33 Diluted $ 0.49 $ 0.33 Weighted average common shares outstanding—basic 35,609 35,374 Weighted average common shares outstanding—diluted 35,933 35,763 NOVANTA INC. CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands of U.S. dollars) (Unaudited) July 1, December 31, 2022 2021 ASSETS Current Assets Cash and cash equivalents $ 100,489 $ 117,393 Accounts receivable, net 129,808 115,617 Inventories 153,887 125,657 Prepaid expenses and other current assets 15,183 15,158 Total current assets 399,367 373,825 Property, plant and equipment, net 87,924 87,439 Operating lease assets 45,575 48,338 Intangible assets, net 193,499 220,989 Goodwill 466,411 479,500 Other assets 13,067 17,792 Total assets $ 1,205,843 $ 1,227,883 LIABILITIES AND STOCKHOLDERS’ EQUITY Current Liabilities Current portion of long-term debt $ 4,678 $ 5,097 Accounts payable 77,351 68,514 Accrued expenses and other current liabilities 116,371 110,327 Total current liabilities 198,400 183,938 Long-term debt 402,679 429,361 Operating lease liabilities 42,580 45,700 Other long-term liabilities 30,015 47,593 Total liabilities 673,674 706,592 Stockholders’ Equity: Total stockholders’ equity 532,169 521,291 Total liabilities and stockholders’ equity $ 1,205,843 $ 1,227,883 NOVANTA INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands of U.S. dollars) (Unaudited) Three Months Ended July 1, July 2, 2022 2021 Cash flows from operating activities: Consolidated net income $ 17,479 $ 11,664 Adjustments to reconcile consolidated net income to net cash provided by operating activities: Depreciation and amortization 13,811 9,875 Share-based compensation 5,081 5,035 Deferred income taxes (4,364 ) 269 Other 3,017 1,638 Changes in assets and liabilities which (used)/provided cash, excluding effects from business acquisitions: Accounts receivable (8,678 ) 248 Inventories (18,581 ) (6,320 ) Other operating assets and liabilities 16,296 6,337 Net cash provided by (used in) operating activities 24,061 28,746 Cash flows from investing activities: Purchases of property, plant and equipment (5,795 ) (5,375 ) Net cash provided by (used in) investing activities (5,795 ) (5,375 ) Cash flows from financing activities: Repayments under term loan and revolving credit facilities (1,193 ) (1,361 ) Payments of debt issuance costs (359 ) — Payments of withholding taxes from share-based awards (1,744 ) (156 ) Repurchases of common shares (10,000 ) — Payment of contingent consideration related to an acquisition — (1,401 ) Other financing activities (148 ) (141 ) Net cash provided by (used in) financing activities (13,444 ) (3,059 ) Effect of exchange rates on cash and cash equivalents (3,138 ) (21 ) Increase (decrease) in cash and cash equivalents 1,684 20,291 Cash and cash equivalents, beginning of period 98,805 113,562 Cash and cash equivalents, end of period $ 100,489 $ 133,853 NOVANTA INC. Revenue by Reportable Segment (In thousands of U.S. dollars) (Unaudited) Three Months Ended July 1, July 2, 2022 2021 Revenue Photonics $ 69,461 $ 62,357 Vision 65,516 63,447 Precision Motion 80,379 41,719 Total $ 215,356 $ 167,523 NOVANTA INC. Reconciliation of GAAP to Non-GAAP Financial Measures (In thousands of U.S. dollars) (Unaudited) Adjusted Gross Profit and Adjusted Gross Profit Margin by Reportable Segment (Non-GAAP): Three Months Ended July 1, July 2, 2022 2021 Photonics Gross Profit (GAAP) $ 31,182 $ 29,593 Gross Profit Margin (GAAP) 44.9 % 47.5 % Amortization of intangible assets 628 784 Acquisition fair value adjustments — — Adjusted Gross Profit (Non-GAAP) $ 31,810 $ 30,377 Adjusted Gross Profit Margin (Non-GAAP) 45.8 % 48.7 % Vision Gross Profit (GAAP) $ 26,535 $ 24,443 Gross Profit Margin (GAAP) 40.5 % 38.5 % Amortization of intangible assets 1,232 1,518 Acquisition fair value adjustments — — Adjusted Gross Profit (Non-GAAP) $ 27,767 $ 25,961 Adjusted Gross Profit Margin (Non-GAAP) 42.4 % 40.9 % Precision Motion Gross Profit (GAAP) $ 38,864 $ 20,874 Gross Profit Margin (GAAP) 48.4 % 50.0 % Amortization of intangible assets 1,476 680 Acquisition fair value adjustments 160 — Adjusted Gross Profit (Non-GAAP) $ 40,500 $ 21,554 Adjusted Gross Profit Margin (Non-GAAP) 50.4 % 51.7 % Unallocated Corporate and Shared Services Gross Profit (GAAP) $ (1,336 ) $ (2,504 ) Amortization of intangible assets — — Employee COVID-19 testing costs 39 1,473 Adjusted Gross Profit (Non-GAAP) $ (1,297 ) $ (1,031 ) Novanta Inc. Gross Profit (GAAP) $ 95,245 $ 72,406 Gross Profit Margin (GAAP) 44.2 % 43.2 % Amortization of intangible assets 3,336 2,982 Acquisition fair value adjustments 160 — Employee COVID-19 testing costs 39 1,473 Adjusted Gross Profit (Non-GAAP) $ 98,780 $ 76,861 Adjusted Gross Profit Margin (Non-GAAP) 45.9 % 45.9 % NOVANTA INC. Reconciliation of GAAP to Non-GAAP Financial Measures (Amounts in thousands except per share amounts) (Unaudited) Adjusted Operating Income and Adjusted Diluted EPS (Non-GAAP): Three Months Ended July 1, 2022 Operating Income Operating Margin Income before Income Taxes Income Tax Provision / (Benefit) Effective Tax Rate Consolidated Net Income Diluted EPS GAAP results $ 23,291 10.8 % $ 20,754 $ 3,275 15.8 % $ 17,479 $ 0.49 Non-GAAP Adjustments: Amortization of intangible assets 10,509 4.9 % 10,509 Restructuring costs 610 0.3 % 610 Acquisition and related costs 2,045 0.9 % 2,045 Acquisition inventory fair value adjustments 160 0.1 % 160 Employee COVID-19 testing costs 39 0.0 % 39 Foreign exchange transaction (gains) losses, net (152 ) Tax effect on non-GAAP adjustments 2,673 Non-GAAP tax adjustments 81 Total non-GAAP adjustments 13,363 6.2 % 13,211 2,754 10,457 0.29 Adjusted results (Non-GAAP) $ 36,654 17.0 % $ 33,965 $ 6,029 17.8 % $ 27,936 $ 0.78 Weighted average shares outstanding - Diluted 35,933 NOVANTA INC. Reconciliation of GAAP to Non-GAAP Financial Measures (Amounts in thousands except per share amounts) (Unaudited) Adjusted Operating Income and Adjusted Diluted EPS (Non-GAAP): Three Months Ended July 2, 2021 Operating Income Operating Margin Income before Income Taxes Income Tax Provision / (Benefit) Effective Tax Rate Consolidated Net Income Diluted EPS GAAP results $ 15,992 9.5 % $ 14,441 $ 2,777 19.2 % $ 11,664 $ 0.33 Non-GAAP Adjustments: Amortization of intangible assets 6,568 3.9 % 6,568 Restructuring costs 1,165 0.7 % 1,165 Acquisition and related costs 3,469 2.1 % 3,469 Employee COVID-19 testing costs 1,473 0.9 % 1,473 Foreign exchange transaction (gains) losses, net 76 Tax effect on non-GAAP adjustments 2,518 Non-GAAP tax adjustments (347 ) Total non-GAAP adjustments 12,675 7.6 % 12,751 2,171 10,580 0.29 Adjusted results (Non-GAAP) $ 28,667 17.1 % $ 27,192 $ 4,948 18.2 % $ 22,244 $ 0.62 Weighted average shares outstanding - Diluted 35,763 NOVANTA INC. Reconciliation of GAAP to Non-GAAP Financial Measures (In thousands of U.S. dollars) (Unaudited) Adjusted EBITDA (Non-GAAP): Three Months Ended July 1, July 2, 2022 2021 Consolidated Net Income (GAAP) $ 17,479 $ 11,664 Consolidated Net Income Margin 8.1 % 7.0 % Interest (income) expense, net 2,757 1,378 Income tax provision (benefit) 3,275 2,777 Depreciation and amortization 13,811 9,875 Share-based compensation 5,081 5,035 Restructuring, acquisition, and related costs 2,655 4,634 Acquisition fair value adjustment 160 - Employee COVID-19 testing costs 39 1,473 Other, net (220 ) 173 Adjusted EBITDA (Non-GAAP) $ 45,037 $ 37,009 Adjusted EBITDA Margin (Non-GAAP) 20.9 % 22.1 % Organic Revenue Growth (Non-GAAP): Three Months Ended July 1, 2022 Compared to Three Months Ended July 2, 2021 Reported Revenue Growth/(Decline) (GAAP) 28.6 % Less: Change attributable to acquisitions 20.9 % Plus: Change due to foreign currency 5.2 % Organic Revenue Growth/(Decline) (Non-GAAP) 12.9 % Net Debt (Non-GAAP): July 1, December 31, 2022 2021 Total Debt (GAAP) $ 407,357 $ 434,458 Plus: Deferred financing costs 5,436 4,126 Gross Debt 412,793 438,584 Less: Cash and cash equivalents (100,489 ) (117,393 ) Net Debt (Non-GAAP) $ 312,304 $ 321,191 Free Cash Flow (Non-GAAP): Three Months Ended July 1, July 2, 2022 2021 Net Cash Provided by Operating Activities (GAAP) $ 24,061 $ 28,746 Less: Purchases of property, plant and equipment (5,795 ) (5,375 ) Plus: Proceeds from sale of property, plant and equipment — — Free Cash Flow (Non-GAAP) $ 18,266 $ 23,371 Consolidated Net Income (GAAP) $ 17,479 $ 11,664 Net Cash Provided by Operating Activities as a Percentage of Consolidated Net Income 137.7 % 246.5 % Free Cash Flow as a Percentage of Consolidated Net Income 104.5 % 200.4 % Non-GAAP Financial Measures Organic Revenue Growth The Company defines the term “organic revenue” as revenue excluding the impact from business acquisitions, divestitures, product line discontinuations, and the effect of foreign currency translation. The Company uses the related term “organic revenue growth” to refer to the financial performance metric of comparing current period organic revenue with the reported revenue of the corresponding period in the prior year. The Company believes that this non-GAAP financial measure, when taken together with our GAAP financial measures, allows the Company and its investors to better measure the Company’s performance and evaluate long-term performance trends. Organic revenue growth also facilitates easier comparisons of the Company’s performance with prior and future periods and relative comparisons to its peers. The Company excludes the effect of foreign currency translation from these measures because foreign currency translation is subject to volatility and can obscure underlying business trends. The Company excludes the effect of acquisitions and divestitures because these activities can vary dramatically between reporting periods and between the Company and its peers, which the Company believes makes comparisons of long-term performance trends difficult for management and investors. Organic Revenue Growth is also used as a performance metric to determine bonus payments for senior management and employees. Adjusted Gross Profit and Adjusted Gross Profit Margin The calculation of Adjusted Gross Profit and Adjusted Gross Profit Margin is displayed in the tables above. Adjusted Gross Profit and Adjusted Gross Profit Margin exclude amortization of acquired intangible assets and inventory fair value adjustments related to business acquisitions because: (1) the amounts are non-cash; (2) the Company cannot influence the timing and amount of future expense recognition; and (3) excluding such expenses provides investors and management better visibility into the underlying trend and performance of our businesses. Additionally, the Company excluded costs directly related to employee COVID-19 testing as these costs are unique to the COVID-19 pandemic and have had a significant impact on the Company’s operating results. Adjusted Operating Income and Adjusted Operating Margin The calculation of Adjusted Operating Income and Adjusted Operating Margin is displayed in the tables above. Adjusted Operating Income and Adjusted Operating Margin exclude amortization of acquired intangible assets and inventory fair value adjustments related to business acquisitions, and costs directly related to employee COVID-19 testing for the reasons described for Adjusted Gross Profit and Adjusted Gross Profit Margin above. The Company also excluded restructuring, acquisition, and related costs due to the significant changes that have occurred outside of the Company’s day-to-day business for the reasons described above in the introductory paragraphs of the “Use of Non-GAAP Financial Measures.” Adjusted Income before Income Taxes The calculation of Adjusted Income before Income Taxes is displayed in the tables above. The calculation of Adjusted Income before Income Taxes excludes amortization of acquired intangible assets and inventory fair value adjustments related to business acquisitions, costs directly related to employee COVID-19 testing, and restructuring, acquisition and related costs for the reasons described for Adjusted Operating Income and Adjusted Operating Margin above. The Company excludes write-off of unamortized deferred financing costs because they only arise in certain specific situations when the Company’s existing credit agreement is terminated or modified. The Company also excluded foreign exchange transaction gains (losses) from the calculation of Adjusted Income before Income Taxes as the Company cannot fully influence the timing and amount of foreign exchange transaction gains (losses). Non-GAAP Income Tax Provision/(Benefit) and Effective Tax Rate The Non-GAAP Income Tax Provision/(Benefit) and Effective Tax Rate are calculated based on the Adjusted Income before Income Taxes by jurisdiction and the applicable tax rates currently in effect for the respective jurisdictions. In addition, the Company excluded significant discrete income tax expenses (benefits) related to releases of valuation allowances, benefits or expenses associated with the completion of tax audits, effects of changes in tax laws, effects of acquisition related tax planning actions on the Company’s effective tax rate, and the income tax effect of non-GAAP adjustments discussed above. Adjusted Consolidated Net Income The calculation of Adjusted Consolidated Net Income is displayed in the tables above. Because income before income taxes is included in determining Consolidated Net Income, the calculation of Adjusted Consolidated Net Income also excludes amortization of acquired intangible assets and inventory fair value adjustments related to business acquisitions, costs directly related to employee COVID-19 testing, restructuring, acquisition and related costs, write-off of unamortized deferred financing costs, and foreign exchange transaction gains (losses) for the reasons described for Adjusted Income before Income Taxes. In addition, the Company excluded significant discrete income tax expenses (benefits) related to releases of valuation allowances, benefits or expenses associated with the completion of tax audits, effects of changes in tax laws, effects of acquisition related tax planning actions on the Company’s effective tax rate, and the income tax effect of non-GAAP adjustments discussed above. Adjusted Diluted EPS The calculation of Adjusted Diluted EPS is displayed in the tables above. Because Consolidated Net Income is used in the calculation of diluted EPS, Adjusted Diluted EPS excludes amortization of acquired intangible assets and inventory fair value adjustments related to business acquisitions, costs directly related to employee COVID-19 testing, restructuring, acquisition and related costs, write-off of unamortized deferred financing costs, foreign exchange transaction gains (losses), significant discrete income tax expenses (benefits) related to releases of valuation allowances, benefits or expenses associated with the completion of tax audits, effects of changes in tax laws, effects of acquisition related tax planning actions on the Company’s effective tax rate, and the income tax effect of non-GAAP adjustments for the reasons described above for Adjusted Consolidated Net Income. Adjusted EBITDA and Adjusted EBITDA Margin The Company defines Adjusted EBITDA as the income before deducting interest (income) expense, income tax provision (benefit), depreciation, amortization, non-cash share-based compensation, costs directly related to employee COVID-19 testing, restructuring, acquisition and related costs, acquisition fair value adjustments, other non-operating (income) expense items, including foreign exchange transaction (gains) losses, write-off of unamortized deferred financing costs, and net periodic pension costs of the Company’s frozen U.K. defined benefit pension plan for the reasons described above in the introductory paragraphs of the “Use of Non-GAAP Financial Measures.” Adjusted EBITDA Margin is defined as Adjusted EBITDA as a percentage of Revenue. In evaluating Adjusted EBITDA and Adjusted EBITDA Margin, you should be aware that in the future the Company may incur expenses that are the same as, or similar to, some of the adjustments in this presentation. Free Cash Flow and Free Cash Flow as a Percentage of Consolidated Net Income The Company defines Free Cash Flow as net cash provided by operating activities less cash paid for purchases of property, plant and equipment and plus cash proceeds from sales of property, plant and equipment. Free Cash Flow as a Percentage of Consolidated Net Income is defined as Free Cash Flow divided by Consolidated Net Income. Management believes these non-GAAP financial measures are important indicators of the Company’s liquidity as well as its ability to service its outstanding debt and to fund future growth. Net Debt The Company defines Net Debt as its total debt as reported on the consolidated balance sheet plus unamortized deferred financing costs and less its cash and cash equivalents as of the end of the period presented. Management uses Net Debt to monitor the Company’s outstanding debt obligations that could not be satisfied by its cash and cash equivalents on hand.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.